Clinical Trials Browser

Phase 1/2 × Neuroendocrine Tumors × olaparib × Clear all

NCT04086485 2025-12-17

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Phase 1/2 Recruiting

Carcinoid Tumor, Neuroendocrine Tumors